 |
|
|
| |
Sofosbuvir/Velpatasvir for 12 Weeks Is Safe and
Effective in Patients Undergoing Dialysis
|
| |
| |
Reported by Jules Levin
AASLD 2018 Nov 9-13 SF
Sergio M. Borgia,1 Janet Dearden,2 Yoav Lurie,3 Stephen D. Shafran,4 Ashley Brown,5 Robert H. Hyland,6 Sophia Lu,6 Svetlana Markova,6 Hadas Dvory-Sobol,6 Anu O. Osinusi,6 Eric M. Yoshida,7 Jose Luis Calleja,8 Edward J. Gane9
1William Osler Health System, Brampton and Toronto, Ontario, Canada; 2Saint Bartholomew's Hospital, London, UK; 3Shaare Zedek Medical Center, Jerusalem, Israel; 4University of Alberta, Edmonton, Canada; 5Imperial College Healthcare NHS Trust, London; 6Gilead Sciences, Inc., Foster City, CA; 7Gordon and Leslie Diamond Health Care Centre, Vancouver, British Columbia, Canada; 8Hospital Universitario Puerta De Hierro-Majadahonda, Spain; 9Auckland City Hospital, Auckland, New Zealand
References: 1. Jacobson IM, et al. N Engl J Med 2013;368:1867-77; 2. Lawitz E, et al. N Engl J Med 2013;368:1878-87; 3. Cheng G, et al. EASL 2013, poster 1191; 4. German P, et al. EASL 2013, poster 1195; 5. Lawitz E, et al. J Vir Hep 2015;22:1011-9; 6. Buggisch P, et al. EASL 2017, poster SAT-254; 7. Curry MP, et al. N Engl J Med 2015;373:2618-28; 8. Curry MP, et al. EASL 2017, abstr PS-102; 9. Feld J, et al. N Engl J Med 2015;373:2599-607; 10. Foster G, et al. N Engl J Med 2015;373:2608-17; 11. Landis C, et al. AASLD 2017, abstr 1096; 12. Lawitz E, et al. Hepatology 2017;66(suppl):848A.
|
| |
|
|
|
|
|
